Brief: Hansa Biopharma Says Study Shows 90% Patient Survival With Imlifidase
17/10/2023 06:20
Oct 17 (Reuters) - Hansa Biopharma AB HNSA.ST :
* IMLIFIDASE DEMONSTRATED 90% PATIENT SURVIVAL AND 82% GRAFT
SURVIVAL AT FIVE YEARS IN EXTENDED POOLED ANALYSIS WITH DATA
FROM 17-HMEDIDES-14 STUDY
Source text for Eikon: ID:nWkr8L90KB
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS